the cliff
Patent cliff
Drugs ranked by the soonest barrier to generic / biosimilar entry. Each row shows the earliest-expiring patent OR FDA exclusivity for that drug — whichever falls first determines when competitive pressure begins.
- Jan 18, 20281.2ypatentNayzilammidazolam [INN]UCB SA
- Jan 20, 20281.2yNCEBrenzavvybexagliflozinTheracosBio LLC
- Jan 22, 20281.2ypatentGocovriamantadine hydrochlorideAdamas Pharmaceuticals Inc
- Jan 22, 20281.2yODE-345Carbaglucarglumic acidRecordati Rare Diseases Inc
- Jan 27, 20281.2yNCEOrserduelacestrant hydrochlorideA. Menarini Industrie Farmaceutiche Riunite Srl
- Jan 27, 20281.2yI-981JaypircapirtobrutinibEli Lilly and Co
- Jan 28, 20281.2ypatentRaltegravirraltegravir potassiumLupin Ltd
- Jan 30, 20281.2ypatentNatazia(dienogest + estradiol valerate)Bayer HealthCare Pharmaceuticals Inc
- Jan 30, 20281.2yNPSymbravo(meloxicam + rizatriptan benzoate)$AXSMAxsome Therapeutics, Inc.
- Jan 30, 20281.2ypatentTrulanceplecanatideSalix Pharmaceuticals Ltd
- Jan 31, 20281.3yD-195PAXLOVID (COPACKAGED)NIRMATRELVIR$PFEPFIZER INC
- Feb 1, 20281.3ypatentAlvescociclesonideCovis Pharmaceuticals Inc (Inactive)
- Feb 2, 20281.3ypatentMETRONIDAZOLEMETRONIDAZOLESaptalis Pharmaceuticals LLC
- Feb 3, 20281.3ypatentTwyneo(benzoyl peroxide + tretinoin)Mayne Pharma USA Inc
- Feb 3, 20281.3ypatentDOXYCYCLINE HYCLATEDOXYCYCLINE HYCLATE$AMRXAmneal Pharmaceuticals, Inc.
- Feb 3, 20281.3yNPApomorphine Hydrochlorideapomorphine hydrochlorideTruPharma LLC
- Feb 3, 20281.3ypatentEpsolaybenzoyl peroxideGalderma Laboratories LP
- Feb 3, 20281.3yODE-325Tepmetkotepotinib hydrochlorideEMD Serono Inc
- Feb 5, 20281.3ypatentZOLEDRONIC ACIDZOLEDRONIC ACIDAvenacy Inc
- Feb 7, 20281.3ypatentDimethyl Fumaratedimethyl fumarateSOLA Pharmaceuticals Inc
- Feb 7, 20281.3yNPPMoxidectinmoxidectinAtticus Medical Pty Ltd
- Feb 17, 20281.3ypatentReyvowlasmiditanEli Lilly and Co
- Feb 17, 20281.3yNCEFilsparisparsentan$TVTXTravere Therapeutics, Inc.
- Feb 21, 20281.3yNPChenodalchenodiol$MIRMMirum Pharmaceuticals, Inc.
- Feb 21, 20281.3yM-14Tofacitinib Citratetofacitinib citrateBiocon Pharma Ltd
- Feb 23, 20281.3ypatentSivextrotedizolid phosphate$MRKMerck & Co., Inc.
- Feb 25, 20281.3yODE-347Amondys 45casimersen$SRPTSarepta Therapeutics, Inc.
- Feb 26, 20281.3yODE-342Nulibryfosdenopterin hydrobromideSentynl Therapeutics Inc
- Mar 1, 20281.3ypatentAdqueydifamilastAcrotech Biopharma Inc
- Mar 3, 20281.3yODE-349Lorbrenalorlatinib$PFEPFIZER INC
- Mar 9, 20281.4yNCEZavzpretzavegepant hydrochloride$PFEPFIZER INC
- Mar 10, 20281.4yNCEDaybuetrofinetide$ACADACADIA PHARMACEUTICALS INC
- Mar 12, 20281.4ypatentCaplytalumateperone tosylateIntra-Cellular Therapies Inc
- Mar 19, 20281.4ypatentXenletalefamulin acetateNabriva Therapeutics US Inc
- Mar 21, 20281.4ypatentHarvoni(ledipasvir + sofosbuvir)$GILDGILEAD SCIENCES, INC.
- Mar 21, 20281.4ypatentVosevi(sofosbuvir + velpatasvir + voxilaprevir)$GILDGILEAD SCIENCES, INC.
- Mar 22, 20281.4ypatentLEUPROLIDE ACETATELEUPROLIDE ACETATE$AMRXAmneal Pharmaceuticals, Inc.
- Mar 22, 20281.4yGAINRezzayorezafungin acetateNapp Pharmaceuticals Ltd
- Mar 24, 20281.4yNCEJoenjaleniolisib [INN]Pharming Group NV
- Mar 26, 20281.4ypatentEdarbyclor(azilsartan medoxomil + chlorthalidone)Azurity Pharmaceuticals Inc
- Mar 26, 20281.4ypatentEdarbiazilsartan kamedoxomilAzurity Pharmaceuticals Inc
- Mar 27, 20281.4ypatentKetotifen Fumarateketotifen fumarateSentiss Pharmaceuticals LLC
- Mar 27, 20281.4yNCERivflozanedosiran sodiumNovo Nordisk AS
- Mar 28, 20281.4ypatentBysantimilsaperidone$VNDAVanda Pharmaceuticals Inc.
- Mar 30, 20281.4ypatentMonistat 7miconazole nitrateInsight Pharmaceuticals LLC
- Apr 7, 20281.4yNPPOzurdexdexamethasone$ABBVAbbVie Inc.
- Apr 25, 20281.5yNCEQalsodytofersen sodium$BIIBBIOGEN INC.
- Apr 26, 20281.5ypatentPramipexole Dihydrochloridepramipexole dihydrochlorideShasun USA Inc
- Apr 30, 20281.5yNPMigranaldihydroergotamine mesylateBausch Health US LLC
- Apr 30, 20281.5yODE-417FerriproxdeferiproneChiesi USA Inc
sourced from FDA Orange Book · approved drugs only · biologics + biosimilars excluded (those live in the Purple Book — coming soon)